Trial site
Tuen Mun Hospital
Hong Kong, 999077, Hong KongNot linked to an institution yet
- 13running trials
- 9closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 2/32 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Completed8 trials
- Not yet recruiting3 trials
- Recruiting2 trials
- Terminated1 trial
- Lead sponsor
- Hoffmann-La Roche7 trials
- Gilead Sciences3 trials
- Pfizer2 trials
- Tuen Mun Hospital2 trials
- Alfasigma S.p.A.1 trial
- and 7 more
Running trials
Not yet recruiting
A Nurse-led Structured Risk Factor Management Program to Improve Quality of Life for Patients With Atrial Fibrillation
NCT07929259· The University of Hong Kong· Source
Contact: Kimmy Wai Ping Chan
Not yet recruiting
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years
NCT07757373· Phase 4· Tuen Mun Hospital· Source
Contact: Chi Chiu Mok, MD, FRCP
Recruiting
Comprehensive Clinical Prediction Rule for Acute Heart Failure
NCT07754084· Chinese University of Hong Kong· Source
Contact: Jeffrey HT Fung, Dr.
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Hoffmann-La Roche· Source
Recruiting
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
NCT07293468· Phase 2/3· Tuen Mun Hospital· Source
Contact: Man TONG
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error